Comparison of the Clinical Outcomes Between Nebulized and Systemic Corticosteroids in the Treatment of Acute Exacerbation of COPD in China (CONTAIN Study): A Post Hoc Analysis

References

• YinP, WangH, VosT, et al. A subnational analysis of mortality and prevalence of COPD in China from 1990 to 2013: findings from the global burden of disease study 2013. Chest. 2016;150:1269–1280. doi:10.1016/j.chest.2016.08.147427693597
   PubMed Web of Science ®Google Scholar
• WangC, XuJ, YangL, et al. Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health [CPH] study): a national cross-sectional study. Lancet. 2018;391:1706–1717. doi:10.1016/S0140-6736(18)30841-929650248
   PubMed Web of Science ®Google Scholar
• VestboJ, HurdSS, AgustiAG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2013;187:347–365. doi:10.1164/rccm.201204-0596PP22878278
   PubMed Web of Science ®Google Scholar
• MathersCD, LoncarD. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006;3:e442. doi:10.1371/journal.pmed.003044217132052
   PubMed Web of Science ®Google Scholar
• PereraPN, ArmstrongEP, SherrillDL, SkrepnekGH. Acute exacerbations of COPD in the United States: inpatient burden and predictors of costs and mortality. COPD. 2012;9:131–141. doi:10.3109/15412555.2011.65023922409371
   PubMedGoogle Scholar
• BouletLP. Asthma and obesity. Clin Exp Allergy. 2013;43:8–21. doi:10.1111/j.1365-2222.2012.04040.x23278876
   PubMed Web of Science ®Google Scholar
• DonaldsonGC, SeemungalTA, PatelIS, et al. Airway and systemic inflammation and decline in lung function in patients with COPD. Chest. 2005;128:1995–2004. doi:10.1378/chest.128.4.199516236847
   PubMed Web of Science ®Google Scholar
• WalshLJ, WongCA, OborneJ, et al. Adverse effects of oral corticosteroids in relation to dose in patients with lung disease. Thorax. 2001;56:279–284. doi:10.1136/thorax.56.4.27911254818
   PubMed Web of Science ®Google Scholar
• DujovneCA, AzarnoffDL. Clinical complications of corticosteroid therapy. A selected review. Med Clin North Am. 1973;57:1331–1342. doi:10.1016/S0025-7125(16)32233-74593202
   PubMed Web of Science ®Google Scholar
• BrogdenRN, McTavishD. Budesonide. An updated review of its pharmacological properties, and therapeutic efficacy in asthma and rhinitis. Drugs. 1992;44:375–407. doi:10.2165/00003495-199244030-000071382936
   PubMed Web of Science ®Google Scholar
• DompelingE, van SchayckCP, MolemaJ, et al. Inhaled beclomethasone improves the course of asthma and COPD. Eur Respir J. 1992;5:945–952.1426202
   PubMed Web of Science ®Google Scholar
• JohanssonSA, AnderssonKE, BrattsandR, GruvstadE, HednerP. Topical and systemic glucocorticoid potencies of budesonide and beclomethasone dipropionate in man. Eur J Clin Pharmacol. 1982;22:523–529. doi:10.1007/BF06096257128664
   PubMed Web of Science ®Google Scholar
• De CosterDA, JonesM. Tailoring of corticosteroids in COPD management. Curr Respir Care Rep. 2014;3:121–132. doi:10.1007/s13665-014-0084-225089228
   PubMedGoogle Scholar
• SunX, HeZ, ZhangJ, et al. Compare the efficacy of inhaled budesonide and systemic methylprednisolone on systemic inflammation of AECOPD. Pulm Pharmacol Ther. 2015;31:111–116. doi:10.1016/j.pupt.2014.09.00425281894
   PubMed Web of Science ®Google Scholar
• ZhangJ, ZhengJ, HuangK, et al. Use of glucocorticoids in patients with COPD exacerbations in China: a retrospective observational study. Ther Adv Respir Dis. 2018;12:1753466618769514. doi:10.1177/175346661876951429692212
   PubMed Web of Science ®Google Scholar
• KiserTH, AllenRR, ValuckRJ, MossM, VandivierRW. Outcomes associated with corticosteroid dosage in critically ill patients with acute exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2014;189:1052–1064. doi:10.1164/rccm.201401-0058OC24617842
   PubMed Web of Science ®Google Scholar
• LindenauerPK, PekowPS, LahtiMC, et al. Association of corticosteroid dose and route of administration with risk of treatment failure in acute exacerbation of chronic obstructive pulmonary disease. JAMA. 2010;303:2359–2367. doi:10.1001/jama.2010.79620551406
   PubMed Web of Science ®Google Scholar
• VondracekSF, HemstreetBA. Retrospective evaluation of systemic corticosteroids for the management of acute exacerbations of chronic obstructive pulmonary disease. Am J Health Syst Pharm. 2006;63:645–652. doi:10.2146/ajhp05031616554288
   PubMed Web of Science ®Google Scholar
• Kiser TH, Sevransky JE, Krishnan JA, et al. Corticosteroid Dosing for Acute Exacerbations of Chronic Obstructive Pulmonary Disease Requiring Ventilatory Support. B23.WHEN I GET HOME: CONFRONTING THE CHALLENGES OF COPD EXACERBATION: American Thoracic Society. 2015;A2540–A2540
   Google Scholar
• HemenwayAN, TerryAM. Evaluation of corticosteroid dose in acute exacerbation of chronic obstructive pulmonary disease. Hosp Pharm. 2017;52:546–550. doi:10.1177/001857871772254029276287
   PubMedGoogle Scholar
• MaltaisF, OstinelliJ, BourbeauJ, et al. Comparison of nebulized budesonide and oral prednisolone with placebo in the treatment of acute exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Am J Respir Crit Care Med. 2002;165:698–703. doi:10.1164/ajrccm.165.5.210909311874817
   PubMed Web of Science ®Google Scholar
• DingZ, LiX, LuY, et al. A randomized, controlled multicentric study of inhaled budesonide and intravenous methylprednisolone in the treatment on acute exacerbation of chronic obstructive pulmonary disease. Respir Med. 2016;121:39–47. doi:10.1016/j.rmed.2016.10.01327888990
   PubMed Web of Science ®Google Scholar
• AlbertRK, MartinTR, LewisSW. Controlled clinical trial of methylprednisolone in patients with chronic bronchitis and acute respiratory insufficiency. Ann Intern Med. 1980;92:753–758. doi:10.7326/0003-4819-92-6-7536770731
   PubMed Web of Science ®Google Scholar
• Gayan-RamirezG, DecramerM. Mechanisms of striated muscle dysfunction during acute exacerbations of COPD. J Appl Physiol. 2013;114:1291–1299. doi:10.1152/japplphysiol.00847.201223372146
   PubMed Web of Science ®Google Scholar
• GunenH, HacievliyagilSS, KosarF, et al. Factors affecting survival of hospitalised patients with COPD. Eur Respir J. 2005;26:234–241. doi:10.1183/09031936.05.0002480416055870
   PubMed Web of Science ®Google Scholar
• FunkGC, BauerP, BurghuberOC, et al. Prevalence and prognosis of COPD in critically ill patients between 1998 and 2008. Eur Respir J. 2013;41:792–799.23018915
   PubMed Web of Science ®Google Scholar
• PapiA, LuppiF, FrancoF, FabbriLM. Pathophysiology of exacerbations of chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2006;3:245–251. doi:10.1513/pats.200512-125SF16636093
   PubMedGoogle Scholar
• BafadhelM, McKennaS, TerryS, et al. Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a randomized placebo-controlled trial. Am J Respir Crit Care Med. 2012;186:48–55. doi:10.1164/rccm.201108-1553OC22447964
   PubMed Web of Science ®Google Scholar
• BafadhelM, McKennaS, TerryS, et al. Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med. 2011;184:662–671. doi:10.1164/rccm.201104-0597OC21680942
   PubMed Web of Science ®Google Scholar
• MathioudakisAG, JanssensW, SivapalanP, et al. Acute exacerbations of chronic obstructive pulmonary disease: in search of diagnostic biomarkers and treatable traits. Thorax. 2020;75:520–527.32217784
   PubMed Web of Science ®Google Scholar